VHC gained 8.2% this week to close at $14.24 — a move that came entirely after Thursday's Q1 results, when the stock jumped 6.2% in a single session.
The earnings backdrop is mixed. Q1 EPS came in at a loss of $1.16 per share, wider than the $1.01 loss a year earlier. The stock rose anyway — a pattern that plays out repeatedly at VirnetX, a patent-licensing company whose moves hinge far more on litigation expectations than on quarterly financials. The next scheduled event is June 11. Whether that date carries legal or financial significance will be a key factor in near-term sentiment.
Short sellers have been moving in the opposite direction to the stock price. Short Interest as a percentage of free float eased slightly to around 3.8%, down roughly 0.4% over the past month. The move is small — positioning has been essentially flat since April — but the direction is consistent. Borrow costs have also fallen sharply, dropping about 24% on the week to 1.77% annualised. That level is genuinely cheap, and the decline mirrors a broader loosening in the lending market. Availability is running at 173%, meaning there are roughly 1.7 times as many shares available to borrow as there are shares already shorted — a comfortable buffer with no sign of squeeze pressure. The ORTEX short score of 60.8 is elevated in absolute terms but has been grinding lower this week, suggesting short-side conviction has eased slightly.
There is no active analyst coverage to speak of — no recent rating changes or price targets are on file. The EV multiple as of December 2025 was roughly $42.5 million, which is consistent with the company's current market cap of around $60 million; VirnetX generates no meaningful operating revenue, so conventional valuation frameworks are largely irrelevant here. The dividend score of 32 reflects the absence of any regular payout — the only notable dividend was a one-time $26 special cash distribution back in 2020, tied to a legal settlement. Factor scores are thin: the ORTEX sector rank of 50 is middling, and the DTC rank of 5 places VirnetX at the low end of the universe for days-to-cover urgency.
The ownership picture is unusually concentrated. CEO and Chairman Kendall Larsen holds 9.7% of shares, with a further 2.5% held by Kathleen Larsen. Together the founding family controls close to 12% of the float. Vanguard and BlackRock hold small passive positions. The only recent insider activity on record was a pair of director sells in November 2025 at prices between $20 and $23 — both small in dollar terms, and both executed when the stock traded well above today's level. That the stock has since retreated from those prices is worth noting in the context of those sales.
Earnings history at VirnetX shows a consistent pattern of sharp short-term moves that don't hold. The April 2026 event delivered an 8% one-day gain followed by a 15% five-day gain; the November 2025 print saw a 5.9% first-day move but ended the following five days down 12.7%. The same fade played out in March 2026. The June 11 event date, and whatever news surrounds it, is the next focal point for positioning.
See the live data behind this article on ORTEX.
Open VHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
